Taking fill release rates to a new level
16-May-2016 | PDF fileDownload PDF Now!
Various attempts by the pharmaceutical industry to reduce cross-linking with additives have only been partially successful. GELITA, however, followed another route: They developed a manufacturing process with a defined and precise molecular size distribution of the RXL gelatine. Small, highly mobile gelatine molecules are, under suitable conditions, able to block the cross-liking effects of the larger gelatine molecules — similar to interfering with the interaction between a key and its lock.
GELITA offers various grades of pharmaceutical gelatine that fit the individual requirements of the manufacturer. The latest development of their Pharmaceutical Competence Team is GELITA® RXL R2 that takes the reduced cross-linking (RXL) concept provided by GELITA® RXL one step further and brings fast release (R²) performance to the market.
Download free e-book